is it time to consider a left ventricular assist device (LVAD)?

In its early stages, heart failure can often be managed with medication and a healthy lifestyle. As the disease progresses and the heart becomes weaker, treatment gets more complex.1 When conventional heart therapies and symptom management strategies are no longer working this stage is considered Advanced Heart Failure.1 

Heart transplant is recognized as a viable treatment option for certain patients with advanced heart failure. However, there are a limited number of donor hearts available. An implanted heart pump, called a left ventricular assist device (LVAD), can help the heart pump oxygen-rich blood throughout the body and has shown sustained improvement in quality of life and functional status.2,3  Patients may once again be able to return to hobbies and enjoyable activities such as exercise, travel, and sex. Compared with medications or pacemakers, LVADs improve quality of life to a far greater degree.4 Read more...

see how HEARTMATETM lvad therapy works with the heart

Watch how the HeartMate 3TM LVAD helps the heart pump oxygen-rich blood through the body.

Heartmate 3 LVAD   watch LVAD animation
image description

see the difference

LVAD therapy has made for heart failure patients

Mayra – Living well with Heart Mate IITM LVAD since 2008

find a heartmateTM lvad advanced Heart Failure Center

HeartMate LVADs are available nationwide. To find a HeartMateTM LVAD center near you, click the button or call our information center, below.

Each testimonial relates an account of an individual's response to the treatment. The patient's account is genuine, typical and documented. However, it does not provide any indication, guide, warranty or guarantee as to the response other persons may have to the treatment. Responses to the treatment discussed can and do vary and are specific to the individual patient. 


Rx Only
Brief Summary: Prior to using these devices, please review the Instructions For Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

HeartMate 3™ LVAS Indications: The HeartMate 3 Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.

HeartMate II™ LVAS Indications: The HeartMate II Left Ventricular Assist System is indicated for use as a “bridge to transplantation” for cardiac transplant candidates who are at risk of imminent death from non-reversible left ventricle failure. It is also indicated for use in patients with New York Heart Association (NYHA) Class IIIB or IV end-stage left ventricular failure, who have received optimal medical therapy for at least 45 of the last 60 days, and who are not candidates for cardiac transplantation. The HeartMate II Left Ventricular Assist System is intended for use both inside and outside of the hospital, or for transportation of Left Ventricular Assist Device patients via ground ambulance, airplane, or helicopter.

HeartMate 3 and HeartMate II LVAS Contraindications: The HeartMate 3 and HeartMate II Left Ventricular Assist Systems are contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

HeartMate 3 and HeartMate II LVAS Adverse Events: Adverse events that may be associated with the use of the HeartMate 3 or HeartMate II Left Ventricular Assist System include, but are not limited to those listed below: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS), thromboembolism, pericardial fluid collection, pump pocket or pseudo pump pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) and pump thrombosis.


1. Advanced heart failure. American Heart Association Web site. Accessed October 25, 2018.  2. Park S, Milano C, Tatooles A, et al. for the HeartMate II Clinical Investigators. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Failure. 2012;5(2), 241-248.  3. Mehra M, Goldstein D, Uriel N, et al. Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. N Engl J Med. 2018;378(15):1386-1395.  4. Givertz, M. Ventricular Assist Devices. Important information for patients and families. Circ Heart Failure. 2011;124:e305-e311.